|Chemical and physical data|
|Molar mass||144479.04 g·mol−1|
|(what is this?)|
Research and development
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
- "Pfizer Pipeline" (PDF). 28 February 2011. Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
- "Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Living Medical eTextbook - Rheumatology - Projects In Knowledge. p. 4. Archived from the original on 24 January 2018. Retrieved 2017-06-07.
- Richardson B. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.